Research Projects All Projects
Projects

Quick links

Development of anti-myostatin vaccine for promotion of livestock animal muscle growth

Project Title: „Development of anti-myostatin vaccine for promotion of livestock animal muscle growth”

Funding: European Regional Development Fund (ERDF), Measure 1.2.1. Specific support goal "To Increase the Private Sector Investments R&D"; measure 1.2.1.2. "Support for Improvement of Technology Transfer System" “Industry‑Driven Research”

Project Nr.: KC-PI-2020/23 

Technical and economic feasibility study and the development of commercialisation strategy that will be accomplished within the first 6 months (19 th July 2017 – 19 th January 2018)

Technical and economic feasibility study and the development of commercialisation strategy costs: 25 000 EUR

Principle Investigator: Dr. biol. K. Tārs

 

 

In the technical and economic feasibility study we plan to (1) estimate the potential market; (2) estimate the final price of the product and compare it to the prices of other growth promoters and commercial benefits; (3) evaluate the technical risks during the project implementation; (4) estimate possibilities of patenting, licensing the patent and licensing the up-scale technology; (5) perform other studies, which might be considered by feasibility study experts. We plan to outsource the performance of technical and economic feasibility study to a suitable company.

 

In this project we propose to use a virus-like particle (VLP) based vaccine, targeting myostatin. VLPs have been used earlier as promoters of immune response and coupling of antigens to them can efficiently overcome tolerance to self-antigens. We have previously demonstrated effectivity of VLP-based vaccines against a variety of diseases, such as Lyme disease and atopic dermatitis in dogs. Our vaccine will consist of correctly folded, recombinant mature myostatin, coupled to VLPs of ssRNA bacteriophages. We expect our vaccine to trigger the production of auto-antibodies against and myostatin, deplete myostatin levels and therefore result in an increase of muscular mass. The costs of such vaccine would be much lower than MAbs and it could be potentially commercially viable, since VLPs and myostatin can be produced in cheaper expression systems such as yeast or Escherichia coli instead of mammalian expression system as is the case with MAbs. Additionally, we believe that combination of VLPs and correctly folded myostatin will lead to substantially higher antibody titers and better muscle growth promotion compared to previously reported vaccine candidates.

Information published 31.03.2020

 

Period: 31.03.2020-30.06.2020

Procurement regulations have been prepared for the procurement "Feasibility study and commercialization strategy development service". The procurement was announced on the website of the Procurement Monitoring Bureau during the period from 18.05.2020. until 29.05.2020 Corporation "KPMG Baltics" was recognized as the winner in the procurement. The contract has been concluded and is being executed.

Information published 30.06.2020.



Mājas lapas izstrādi finansēja ERAF 2.1.1.2. aktivitātes projekts Nr. 2010/0196/2DP/2.1.1.2.0/10/APIA/VIAA/004 "Latvijas biomedicīnas pētījumu integrācija Eiropas zinātnes telpā".